































































The pharmacokinetics and drug-drug
interactions of ivermectin in Aedes aegypti
mosquitoes
Urs DuthalerID
1,2☯*, Michael Weber1,2☯, Lorenz HoferID3,4, Carlos ChaccourID5,6,7,
Marta MaiaID
8,9, Pie MüllerID
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Abstract
Mosquitoes are vectors of major diseases such as dengue fever and malaria. Mass drug
administration of endectocides to humans and livestock is a promising complementary
approach to current insecticide-based vector control measures. The aim of this study was to
establish an insect model for pharmacokinetic and drug-drug interaction studies to develop
sustainable endectocides for vector control. Female Aedes aegypti mosquitoes were fed
with human blood containing either ivermectin alone or ivermectin in combination with keto-
conazole, rifampicin, ritonavir, or piperonyl butoxide. Drug concentrations were quantified
by LC-MS/MS at selected time points post-feeding. Primary pharmacokinetic parameters
and extent of drug-drug interactions were calculated by pharmacometric modelling. Lastly,
the drug effect of the treatments was examined. The mosquitoes could be dosed with a high
precision (%CV:�13.4%) over a range of 0.01–1 μg/ml ivermectin without showing satura-
tion (R2: 0.99). The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h
(CI90%: 17.0–19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1–
5.9 pg/h). By contrast, ketoconazole, ritonavir, and piperonyl butoxide were immediately
excreted following first order elimination, whereas rifampicin accumulated over days in the
mosquitoes. Ritonavir increased the lag phase of ivermectin by 11.4 h (CI90%: 8.7–14.2 h)
resulting in an increased exposure (+29%) and an enhanced mosquitocidal effect. In sum-
mary, this study shows that the pharmacokinetics of drugs can be investigated and modu-
lated in an Ae. aegypti animal model. This may help in the development of novel vector-
control interventions and further our understanding of toxicology in arthropods.
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Author summary
Mosquitoes are responsible for the transmission of pathogens, which cause diseases that
are of major health significance such as dengue fever and malaria. Preventive strategies
involving the use of insecticides, however, have led to the emergence of resistant mosqui-
toes. Consequently, development of complementary approaches is urgently needed to
stop the spread of these pathogens. Our study reports on a pioneering approach to investi-
gate how well drugs are taken up by the mosquitoes and how long they reside in their
body. We focused on ivermectin, which is toxic for mosquitoes, and several drugs that
interfere with drug metabolising enzymes. We demonstrated that the exposure of drugs
can be precisely determined in individual mosquitoes and that drugs interact with each
other in the same way as observed in vertebrates. In this regard, we were able to increase
the exposure and mosquito toxicity of ivermectin by co-administering ritonavir, a broad-
spectrum inhibitor of drug metabolising enzymes. This study establishes Aedes mosqui-
toes as a new model organism for pharmacokinetic studies. It opens the door for the
investigation of novel insecticide strategies and optimisation of lead compounds against
mosquitoes.
Introduction
The World Health Organization (WHO) estimates vector-borne diseases to account for more
than 17% of all infectious diseases [1]. Arthropods such as mosquitoes, sand flies, and ticks are
arguably the most important disease vectors. Mosquitoes in particular transmit diseases that
are a major threat to global health. In 2018 alone, Anopheles mosquitoes caused an estimated
228 million malaria cases resulting in 405,000 deaths [2]. With the global spread of the highly
efficient urban vector Aedes aegypti, increasing international travel, and climate change,
arthropod-borne viruses (arboviruses) including dengue, Zika, yellow fever and chikungunya
are (re-)emerging [3]. Besides malaria, dengue fever has the highest disease burden globally
with an estimated annual incidence of 390 million and with about half the world’s population
being at risk [4,5].
Although efforts are underway to develop novel drugs and vaccines against mosquito-
borne pathogens, drug resistance and an impervious protective immunity are major obstacles
towards eradicating these diseases. In addition, many vector control interventions such as
indoor residual spraying and insecticide-treated nets seem to be reaching an efficacy plateau as
mosquitoes adapt their behaviour or develop insecticide resistance [6,7].
A novel potential complementary approach to vector control is mass administration of
endectocidal drugs to humans and livestock. Modelling and preliminary clinical trials using
the antiparasitic drug ivermectin have shown that this strategy could effectively reduce malaria
transmission by targeting the mosquito population [8,9]. Ivermectin is lethal for Anopheles
mosquitoes already in the low nanomolar range, while sub-lethal concentrations lead to mos-
quitoes to producing fewer offspring [10–12]. Ivermectin is less effective against Aedes mos-
quitoes on the other hand: while a single oral dose of 150 μg/kg yields host blood
concentrations lethal to Anopheles mosquitoes, it would only reach within 10% of the LD50 for
similar effects against Ae. aegypti [13]. Thus, ivermectin is not considered a candidate endecto-
cide for arboviral disease control [14]. Nevertheless, Aedes mosquitoes serve as a good model
system to study the pharmacokinetics (PK) and drug-drug interactions of endectocides,
because laboratory strains are simple to rear and readily membrane-feed on human blood.
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Moreover, Ae. aegypti’s tolerance to high ivermectin concentrations allows for drug quantifica-
tion in single mosquitoes.
Effective control with mass drug administration requires a large proportion of the human
population to receive the drug. The intake of co-medications for concomitant disorders may
impact the efficacy and safety of the intervention through drug-drug interactions in the host
and the mosquito. Tuberculosis and HIV/AIDS present the greatest challenge, as they are
widely co-endemic with mosquito-borne diseases. The growing availability of medical care
results in a considerable share of the human target populations receiving medication that may
lead to relevant drug-drug interactions [15], but potentially also in the mosquito. Rifampicin,
one of the mainstays of tuberculosis treatment, is also one of the strongest activators of the
nuclear pregnane X receptor (PXR). PXR is associated with a wide variety of drug-metabolis-
ing enzymes and drug transporters such as cytochrome P450 3A4 (CYP3A4) and p-glycopro-
tein (Pgp), both of which ivermectin interacts with. HIV anti-retroviral therapy may consist of
broad CYP inhibitors and/or inducers such as the protease inhibitor ritonavir. Ivermectin itself
is metabolised by CYP3A4 by which it is demethylated at the disaccharide substituent and/or
hydroxylated at several positions of the aglycon [16]. It is unknown to what extent the metabo-
lites contribute to the activity of ivermectin, thus the impact of CYP induction or inhibition is
difficult to estimate [17]. A drug interaction study in pigs showed, however, that co-adminis-
tration of ivermectin and ketoconazole, a strong inhibitor of CYP3A4, increased ivermectin´s
activity against Anopheles gambiae mosquitoes [18]. The study concluded that co-medications
may affect the PK of endectocides within humans, while drug-drug interactions may be equally
possible in the arthropod vector. Overall, interactions at both sites might compromise the suc-
cess of mass endectocide administration.
The aim of the present study was to investigate the PK of ivermectin and its interaction
with co-administered medications in Ae. aegypti mosquitoes. Ivermectin was administered by
membrane blood feeding either alone or in combination with ketoconazole, ritonavir, rifampi-
cin, or piperonyl butoxide, an unselective inhibitor of CYPs in insects [19]. While conven-
tional pharmacokinetic modelling describes concentration profiles in central or effect
compartments, measuring systemic concentrations in mosquito tissues is impossible from a
technical and anatomical standpoint. As a result, only whole specimens can be analysed at the
scale required for pharmacokinetic studies. Therefore, a sparse-sampling population model-
ling approach based on the time course of whole-body amounts in individual mosquitoes was
implemented. Concentration-time profiles were created based on drug level measurements of
single mosquitoes, whereas the primary pharmacokinetic parameters and the effect of drug-
drug interactions on model parameters such as clearance were assessed by pharmacometric
modelling.
Results
Raw data of the main and supporting information figures are given in S1 Data
Mosquito dosing experiments. The ability to quantify ivermectin in a single mosquito at
different time points post treatment and to dose them precisely were important prerequisites
for investigating the PK properties of ivermectin in mosquitoes. The dosing precision (%CV)
was within 7.1% to 13.4% when adjusted for mosquito weight (Fig 1). The bias was larger
(17.7–19.3%) by calculating the ivermectin concentration per individual mosquito, thus the
concentration data were henceforth normalised by the body weight.
A linear relationship was found between the dose in the blood meal and the amount recov-
ered from the mosquitoes (R2: 0.99). Within the range tested, no saturation was observed, indi-
cating that the mosquitoes neither imbibed less blood at higher ivermectin concentrations nor
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was the diuresis after blood intake altered by ivermectin intake (Fig 1). Importantly, ivermectin
could be quantified over three orders of magnitude in single mosquitoes. Based on these data,
a relatively low concentration of 0.1 μg/ml ivermectin could be chosen for PK experiments
under which most mosquitoes survived longer than three days.
Pharmacokinetic studies
Pharmacometric analysis of ivermectin. In total, 1108 mosquitoes were analysed by
LC-MS/MS; 12 less than planned, because a large percentage of the mosquitoes died 48 h after
treatment with ivermectin plus ritonavir. The ivermectin concentration was below the lower
limit of quantification in 34 samples, 33 of which were collected 72 h post treatment.
All models were built on the total amounts of substance detected in each mosquito. For the
basic structural model, the mosquito was assumed as a single compartment from which the
drug disappears. Different types of elimination (zero-order, first-order, Michaelis-Menten)
were evaluated while allowing for a lag parameter until the onset of drug elimination. The final
basic model was a one-compartment model with zero-order elimination, a lag time parameter,
and an estimation of the amount absorbed from the blood meal (as bioavailability F1 from a
standard dose).
Covariates considered in the analysis were weight, batch number, and co-administered
drugs. Weight was standardized to the median mosquito weight of 3.4 mg and entered as a
covariate on dose absorbed and elimination rate (kel) with allometric scaling. Inter-occasion
variability was observed for the dose administered between different feeding batches. Ritonavir
co-treatment was explanatory for the prolonged lag time until elimination in the respective
batches. We found no other interaction of the co-administered drugs with the PK of ivermec-






























Fig 1. Ivermectin dosing precision and linearity of Aedes aegypti mosquitoes. Mosquitoes (n = 30) were treated
with blood containing 0.01, 0.05, 0.1, 0.5, and 1 μg/ml ivermectin. The amount of ivermectin shows a linear
relationship with the applied concentration in blood (regression line R2: 0.99, black dashed line), while the coefficient
of variation (CV%) was�13.4% (numbers above the regression line). The grey circles correspond to ivermectin
amounts recovered from single extracted mosquitoes. The red cross depicts the median amount of ivermectin
recovered from the mosquitoes.
https://doi.org/10.1371/journal.ppat.1009382.g001
PLOS PATHOGENS Pharmacokinetics of ivermectin in Aedes aegypti mosquitoes
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009382 March 17, 2021 4 / 18
Parameter estimates and results of the bootstrap analysis (n = 1000) are shown in Table 1. A
total number of 68 runs failed and were excluded from the analysis. Basic goodness-of-fit plots
and visual predictive checks by co-administered drug are shown in Figs 2 and S1, respectively.
The diagnostic plots show that the observed data are captured well by the final model.
Concentration-time courses of ivermectin and cytochrome P450 modulators in Aedes
aegypti. Human blood spiked with 0.1 μg/ml ivermectin was administered to four Ae. aegypti
batches, each including at least 140 mosquitoes (Figs 3 and S2). The mosquitoes imbibed on
average 0.36 ± 0.06 (SD) ng of ivermectin per feeding, which corresponds to 3.6 μl of blood.
The mean weight of a mosquito measured directly after the feeding was 4.5 mg and varied
between the mosquito batches between 3.9–5.0 mg (S3 Fig). In the first 18 h after blood-feed-
ing (lag phase) the mosquitoes eliminated excess liquid from the blood meal, with the effect
that the concentration of ivermectin remained stable or even increased in the mosquitoes. Fol-
lowing the lag phase, ivermectin was slowly eliminated between 12–24 h post-feeding and after
72 h only traces of ivermectin were still detectable. Overall, the rate of the blood meal digestion
was comparable between mosquito batches, resulting in weight loss of 50.7–54.6% over 72 h.
We determined the amounts of CYP450 modulators administered alongside ivermectin to
gauge uptake and duration of exposure. Concentration-time profiles are shown in Fig 3. Keto-
conazole was eliminated rapidly, with 75% of the dose being excreted already after 6 h, while
only few samples could be quantified 36 h post-feeding. No effect on the concentration-time
course of ivermectin was observed. In contrast to ketoconazole, rifampicin signals slowly
increased in the mosquitoes and reached maximal concentrations approximately after 36 h.
Rifampicin was almost not eliminated during the first 2 days, yet the mosquitoes halved their
body weight following digestion of the blood meal (S3 Fig). The concentration-time course of
ivermectin alone and in combination with rifampicin matched during the entire observation
period of 72 h. Thus, rifampicin did not alter the PK of ivermectin. Piperonyl butoxide elimi-
nation appeared linear and it was almost completely excreted from the mosquitoes after 36 h.
Like the other two CYP modulator, piperonyl butoxide did not change the PK of ivermectin in
Ae. aegypti mosquitoes. Exclusively ritonavir, that appeared to follow first order elimination,
influenced the disposition of ivermectin. Ritonavir delayed the start of ivermectin elimination
by approximately 11.4 h, resulting in a 29% increased AUC compared to ivermectin alone.
Interestingly, the elimination rate of ivermectin was not affected by ritonavir.
Table 1. Final parameter estimates and results of a non-parametric bootstrap analysis (1’000 runs). %RSE: relative standard error (%RSE = 100 x standard error/
parameter estimate), CI: confidence interval, kel: elimination rate, Tlag: lag time to elimination, Tlag_add_rit: additional lag time to elimination in ritonavir co-treatment,
IOV: inter-occasion variability.
Bootstrap analysis (n = 1’000)
Parameter Estimate %RSE Median CI 90%
Fixed effects
dose [ng] 0.28 0.6 0.28 0.277–0.283
kel [ng/h] 0.0055 5.2 0.055 0.0051–0.0059
Tlag [h] 18.5 4.5 18.5 17.0–19.8
Tlag_add_rit [h] 11.4 14.0 11.4 8.7–14.2
Inter-individual variability (ω)
dose 0.075 41.4 0.075 0.062–0.086
kel 0.25 13.8 0.25 0.20–0.30
IOV dose 0.11 6.9 0.11 0.08–0.12
Residual Errors (σ)
proportional 0.02 39.7 0.02 0.01–0.03
additive 0.018 27.1 0.018 0.009–0.026
https://doi.org/10.1371/journal.ppat.1009382.t001
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Drug effect of the treatments
The effect of ivermectin, ketoconazole, rifampicin, ritonavir, and piperonyl butoxide on mos-
quito mortality, fecundity, and fertility was investigated. The results of the drug combinations
including ivermectin plus ketoconazole, rifampicin, ritonavir, or piperonyl butoxide were
compared with the respective drugs administered alone. In the control groups, mosquitoes
received a drug-free blood meal (blank blood).
After a blank blood meal, 92% of the mosquitoes survived for four days in the climate
chamber (Fig 4). Monotherapy with ketoconazole, rifampicin, ritonavir, and piperonyl butox-
ide resulted in four-day mosquito mortality of 10–13%, whereas ivermectin killed 17% of the
mosquitoes in the first four days. The four-day mosquito mortality of ivermectin plus ketoco-
nazole, rifampicin, and piperonyl butoxide was 19%, 12%, and 27%, respectively, suggesting
no additive effect. In contrast, the combination of ivermectin and ritonavir killed 42% of the




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0 10 20 30 40 50
hours
Time post feeding
Observed data vs. individual predictions
emit revo SERWCsnoitciderp laudividni .sv SERWC
0.1 0.3 0.5
0.1 0.2 0.3 0.4 0.50.0
Fig 2. Goodness-of-fit plots for the final model (dashed lines: Local weighted smooth). Observed data vs. population predictions (top left), observed data vs.
individual predictions (top right), absolute conditional weighted residuals (CWRES) vs. individual predictions (bottom left), and CWRES over time (bottom right).
https://doi.org/10.1371/journal.ppat.1009382.g002
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value < 0.001 compared to treatments with blank blood, or ivermectin alone). Ivermectin was
the only drug that reduced the number of mosquito eggs compared to blank blood feedings
(p-value < 0.023 compared to treatments with blank blood). This effect was even stronger
when ivermectin was combined with ritonavir (p-value < 0.001) or PBO (p-value < 0.02)
compared to blank blood treatments.
After feeding the mosquitoes blank blood, 83% (CI95%: 72%-94%) of the eggs were fertile
and produced live larvae. The CYP modulators did not reduce the fertility of the mosquitoes
considering that 72% to 81% of the eggs produced live larvae. Ivermectin alone sterilised
almost all mosquito eggs (p-value < 0.04 compared to blank blood treatments) and, therefore,
no increased effect would be observable for ivermectin combinations even if there were an
effect.
Overall, when exposed to the sub lethal concentrations of ivermectin used in this study,
mosquitoes were almost infertile, while their survival was notably reduced by the co-medica-
tion with ritonavir.
Discussion
Mass administration of endectocidal drugs might be a valuable addition to insecticide-treated
bed nets and indoor residual spraying because it offers the opportunity to also target mosqui-
toes that bite outdoors or have diurnal activity. However, co-medications may impact the
effectiveness of mass drug administration campaigns by changing drug disposition not only in
treated humans but also in the mosquito. PK investigations in mosquitoes are, therefore, not
only crucial for investigating antagonistic or synergistic drug-drug interactions, but also for
optimising lead compounds and determine species- or population-specific differences. Our
study demonstrates that the PK of small molecules can be assessed in blood-feeding
Fig 3. Concentration-time course of ivermectin single and combination treatments in Aedes aegypti mosquitoes. Aedes aegypti mosquitoes were
treated with ivermectin (IVM: 0.1 μg/ml) alone or in combination with ketoconazole (KCZ: 5 μg/ml), rifampicin (RIF:10 μg/ml), ritonavir (RTV: 10 μg/ml),
or piperonyl butoxide (PBO: 10 μg/ml). At 0, 6, 12, 24, 48, and 72 h post treatment, the drug concentration in up to 20 live mosquitoes was analysed.
Concentration-time profiles of ivermectin single and combination treatments are illustrated in the left column and the profile of the respective CYP
modulator in the right column. Large circles depict the mean concentration and the small circles (single treatment: white, combination treatment: red)












































































































































Fig 4. Drug effect of mono- and combination treatments on mosquito mortality, fecundity, and fertility. Aedes aegypti mosquitoes were treated with blank human
blood, blood containing ivermectin (IVM: 0.1 μg/ml), ketoconazole (KCZ: 5 μg/ml), rifampicin (RIF: 10 μg/ml), ritonavir (RTV: 10 μg/ml) or piperonyl butoxide (PBO:
10 μg/ml), or a drug combination of ivermectin (0.1 μg/ml) plus ketoconazole (5 μg/ml), rifampicin (10 μg/ml), ritonavir (RTV: 10 μg/ml) or piperonyl butoxide (10 μg/
ml). 3 batches of 50 mosquitoes were investigated per treatment group. Median percentage survival of the mosquitoes was assessed after 1, 2, 3, and 4 days. The error
bars correspond to the range. The fecundity, the amount of eggs excreted, and fertility, the proportion of hatched larvae, were measured after 4 days. The floating-bars
display the range and the line in the middle the median value.
https://doi.org/10.1371/journal.ppat.1009382.g004
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mosquitoes and reveals that each investigated compound exhibited unique kinetic characteris-
tics. Furthermore, we showed that the disposition of ivermectin can be modulated by co-treat-
ment of ritonavir, thereby increasing the mosquitocidal activity.
The first prerequisite for realising PK investigations in mosquitoes is a consistent volume of
the blood ingested across individuals to allow for precise dosing. Ivermectin concentrations
and body weight as determined directly after the mosquitoes had fed from the membrane
feeder varied by less than 13.4% and 15%, respectively, showing that the blood intake of Ae.
aegypti mosquitoes was very uniform. The second prerequisite is that the drug in the meal
does not affect blood intake. Overall, the mosquitoes ingested a consistent volume of blood,
regardless of the ivermectin concentration (0.01–1 μg/ml), considering that the mosquito
weights were very similar across the different treatment dosages (range: 3.0–3.3 mg). More-
over, a strong linear relationship was observed between the administered ivermectin blood
concentration and the amount measured in the mosquitoes (Fig 1). Conveniently, also high
ivermectin dosages did not exert a repelling effect on Ae. aegypti mosquitoes, and the extrac-
tion recovery of the bioanalytical method was reproducible over at least two orders of magni-
tude without saturation. Finally, the method sensitivity was sufficient to quantify 98.5% of the
elimination process of ivermectin in single mosquitoes, demonstrating that this setup allows
for measuring the PK over a large dynamic range.
The mosquitoes ingested on average 3.6 μl blood, based on the amount of ivermectin mea-
sured after the feeding. This is on par with previous studies that found the volume of a regular
blood meal ranging between 2.4 to 4.5 μl [20–22]. The weight loss over 72 h was on average 2.4
mg, corresponding to about 2.3 μl blood (δBlood: 1.06), thus approximately 1.4 mg less than
expected, assuming that blood digestion was complete. However, the digestion process was
most likely not terminated at this time point because, according to Redington and Hockmeyer
(1976), it takes around four days to completely excrete radiolabelled blood [22]. Furthermore,
the blood uptake is underestimated by gravimetric measurements given that approximately
20–30% of the total imbibed fluid is excreted by the mosquitoes during and for up to 3 h after
the feeding [22,23]. It was striking that immediately after feeding (T0), especially ketoconazole
and rifampicin concentrations were considerably lower than what would be expected from the
amount of blood taken up by the mosquitoes. The mosquitoes were allowed to feed for 20 min
on blood while they were already excreting large amounts of liquid during diuresis, which pos-
sibly contained significant quantities of the drugs. Another potential reason for the observed
discrepancy could be that the drugs were rapidly metabolised during the feeding in the insect’s
midgut. Lastly, it cannot be excluded that ketoconazole and rifampicin were incompletely
recovered by the employed extraction method.
To the best of our knowledge, this is the first drug-drug interaction study using arthropods
as model organisms, and the first to determine the PK properties of ivermectin in mosquitoes.
Studies in ruminants and humans have shown that the highly lipophilic ivermectin binds
strongly to plasma proteins, distributes widely in the body, while accumulating in fatty tissue,
leading to a prolonged elimination [24,25]. In Ae. aegypti, ivermectin accumulates in the mos-
quitoes during an initial lag phase of around 18 h before being slowly eliminated over a period
of 2 days. In contrast to the exponential decay observed in mammalian species, ivermectin
elimination in mosquitoes followed zero-order kinetics. The concentration-time profile of
rifampicin resembled the one of ivermectin, whereas the amplitude of the rifampicin curve
was greater. Ketoconazole, piperonyl butoxide and ritonavir, on the other hand, followed a
first order elimination similar to observations made with radio labelled 14C-permethrin, which
was applied topically on the sternum or notum of Ae. aegypti mosquitoes. There, permethrin
was transformed by CYPs to hydroxy-permethrin and other more hydrophilic metabolites
PLOS PATHOGENS Pharmacokinetics of ivermectin in Aedes aegypti mosquitoes
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[26]. Involvement of CYP metabolism in Ae. aegypti is also conceivable for piperonyl butoxide
as it is known to be a substrate of mammal as well as insect CYPs [19].
Ritonavir was the only CYP modulator, which significantly increased ivermectin levels in
the mosquitoes. It is a broad-spectrum inhibitor of human CYPs, UGTs, and of the efflux
pump P-glycoprotein and other drug transporters [27]. Ritonavir prolonged the lag-time of
ivermectin by about 11 hours but not the elimination rate, which might be an indication that
an efflux pump rather than the function of metabolic enzymes was inhibited. This is plausible
as the Ae. aegypti genome consists of numerous putative adenosine triphosphate binding cas-
sette (ABC) transporters including multidrug efflux proteins [28]. Considering that piperonyl
butoxide did not influence the PK of ivermectin, even though many studies demonstrated that
it is a potent and non-selective inhibitor of CYPs in mammals and invertebrates, supports this
hypothesis [29]. However, it cannot be excluded that its inhibitory capacity was hindered due
to the lower bioavailability of the oral compared to topical route of application. Interestingly,
Chaccour and colleagues observed that ketoconazole increased the exposure of ivermectin in
pigs as well as the activity of ivermectin against An. gambiae mosquitoes possibly by inhibiting
CYPs in both organisms [18]. However, the exposure and efficacy of ivermectin in Ae. aegypti
was not altered by ketoconazole co-treatment, potentially because Ae. aegypti possesses a larger
pool of detoxification genes than An. gambiae, leading to rapid inactivation of ketoconazole
[30]. Fast elimination was observed in Ae. aegypti, however the pharmacokinetic interaction of
ivermectin and ketoconazole must be investigated in Anopheles mosquitoes to understand
those species differences. Major classes of inducers of vertebrate CYPs such as barbiturates
and alkaloids are also functional in insects [31]. Nevertheless, rifampicin, which is a potent
inducer of numerous CYPs, members of the uridine 5’-diphospho-glucuronosyltransferases
(UGT), and the efflux transporter P-glycoprotein in humans [32], did not accelerate elimina-
tion of ivermectin in Ae. aegypti. This result must be interpreted with caution, because the
increase of the protein pool is not immediate, requiring usually pre-exposure to the inducer
over several days [32–34]. Given that in the wild exposure to rifampicin would occur simulta-
neously with ivermectin, our study allows for a realistic estimate of the impact of this interac-
tion. Overall, quantification of ivermectin metabolites and analysis of the mosquito
excrements would have been prerequisite to elucidate the mechanism of drug interactions in
Ae. aegypti.
Ivermectin is only active against Aedes mosquitoes at blood concentrations that cannot be
obtained in humans receiving a regular dose [13,35]. Studying the pharmacokinetics of iver-
mectin in Aedes spp. has the advantage that higher dosages can be administered, which facili-
tates sampling of live mosquitoes and drug quantification in single specimens. Nonetheless,
the use of Aedes as model to infer information that pertains to ivermectin as endectocide
remains unclear and necessitates comparative studies in highly susceptible mosquito species
such as An. gambiae [36]. Importantly, the pharmacokinetic interaction between ritonavir and
ivermectin translated into a more pronounced effect considering that the mosquito mortality
increased, and the number of eggs laid decreased. Ivermectin reduced the fertility and fecun-
dity of Ae. aegypti mosquitoes, which is in line with previous observations [37–39]. However,
the effect on the hatching rate was more pronounced than reported by Focks and Hadlett
[35,40], arguably because the susceptibility varies between Ae. aegypti strains [38]. The effect
on the ovarian development should not be overrated given that the reduced fecundity and fer-
tility ends when ivermectin is discontinued [37].
In conclusion, this study demonstrates for the first time that the PK of ivermectin can be
measured in mosquitoes upon blood feeding. The kinetic properties of ivermectin can be mod-
ulated by co-administered drugs leading to increased mosquitocidal activity. The current
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method will advance our understanding of endectocidal pharmacology in mosquitoes and
may help in designing novel or improving existing compounds for mosquito control.
Materials and methods
Chemicals, reagents and reference substances
Ammonium format and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich
(Buchs, Switzerland). Gradient grade methanol, water, formic acid (FoA, 98–100%), isopropyl
alcohol, and acetonitrile were products of Merck (Darmstadt, Germany). Human blank blood,
stabilised by citrate-phosphate-derivative with adenine, was obtained from the local blood
donation centre.
Ivermectin and ritonavir as well as the internal standard ivermectin-d2 were purchased
from Toronto Research Chemicals (Toronto, Canada). Rifampicin, ketoconazole, and pipero-
nyl butoxide were obtained from Sigma-Aldrich.
Mosquito rearing
Ae. aegypti Rockefeller strain were reared under constant temperature (27˚ C ± 2˚ C) and
humidity (70% ± 10%) conditions, and at a 12:12 hours light dark cycle. Female and male mos-
quitoes were kept in the same cage to allow for mating to occur. Females were membrane fed
once a week with fresh pig blood received from the local abattoir. Eggs were harvested on
round filter papers (⌀: 8 cm, Sartorius, Göttingen, Germany) placed on top of a moist sponge
that was kept in a glass bowl. The eggs were then left to sclerotize and dry for seven days in the
insectary. The eggs were hatched by placing a slice of the egg-coated filter paper in a glass dish
filled with tap water treated with 0.012% (v/v) AquaSafe (Aquasafe, Seevetal, Germany). About
300 larvae were transferred into white plastic trays containing 600 ml AquaSafe-treated water.
The larvae were cultivated in an incubator (Aqualytic, Dortmund, Germany) set at 27˚ C and
fed with TetraMin fish food (Tetra, Melle, Germany) on a daily basis. Once the larvae reached
the 4th instar they were transferred into emergence cages (375 mm x 445 x mm 495 mm) and
adults were provided with 10% aqueous sucrose solution ad libitum.
Pharmacokinetic studies in Aedes aegypti mosquitoes
Mosquito treatments. Drug stock solutions were prepared in DMSO and added to
blank human blood at a ratio of 1:1000 so that the DMSO content was less than 0.2%. The
mixtures were rotated at room temperature for 30 min to ensure a uniform drug distribution
(Rotator Genie, Scientific Industries, Bohemia, USA). The sugar water within the mosquito
cages was replaced by tap water 24 h prior to the PK experiments. Twelve hours later, the tap
water was also removed to starve the mosquitoes. On the day of the PK experiment, 25–35
starved, female mosquitoes with an age of 6–7 days post-emergence were transferred with a
mouth aspirator into 2 dl paper cups that were sealed with a piece of mosquito netting. The
blood samples were heated in a water bath (SAHARA PPO S5P Heated Bath Circulators,
Thermo Fisher Scientific, New Hampshire, USA) for 20 min at 39.5˚C. A petri dish (35 mm
x 10 mm, BD, Franklin Lakes, USA) was filled with 2.55 ml of warm blood, sealed with a
piece of Parafilm (Parafilm M sealing film, Huberlab AG, Aesch, Switzerland) stretched over
the rim and turned upside down on top of the paper cup. The mosquitoes were then feeding
from blood through the netting and the Parafilm membrane. The feeding was conducted in a
climate chamber (HPP110, Memmert GmbH + Co.KG, Schwabach, Germany) at 26˚ C, 70%
humidity, and 50% light intensity. The photoperiod of the climate chamber and the insectary
were synchronised. After 20 min of feeding, the cups were placed on ice to immobilise the
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mosquitoes and separate the fully engorged ones. The engorged mosquitoes were either
directly frozen at -20˚C or returned to the climate chamber for certain time periods to assess
the PK.
Mosquito dosing experiments. The first aim was to evaluate the variability of the blood
uptake by the mosquitoes. Batches of 30 Ae. aegypti mosquitoes were fed on human blank blood
containing either 0.01, 0.05, 0.1, 0.5 or 1 μg/ml ivermectin. The dosing precision was estimated
by the coefficient of variation (CV%), i.e. the ratio of the standard deviation to the mean (Excel
Office 365, Microsoft, Washington, USA). The second aim was to measure the association
between the ivermectin concentration in the blood and the amount recovered from the mosqui-
toes. The strength of the association was assessed using a linear regression model and its correla-
tion coefficient R2 using GraphPad prism software 9.0.0 (San Diego, USA). On the basis of these
results an optimal dose for the PK experiments was chosen yielding a strong ivermectin baseline
signal while keeping its concentration at a level sub-lethal for the mosquitoes.
Pharmacokinetic studies. Based on the dosing experiments, female mosquitoes were
membrane fed human blood containing 0.1 μg/ml ivermectin alone or a combination of iver-
mectin (0.1 μg/mL) with one of the following CYP modulators: ritonavir (10 μg/ml), ketocona-
zole (5 μg/ml), rifampicin (10 μg/ml), or PBO (10 μg/ml). The treatments were carried-out on
four different occasions (four batches of mosquitoes), in which ivermectin was always admin-
istered alone as well as in combination with one of the four CYP modulators. Consequently,
the effect of the combination therapy could be compared one-to-one with the monotherapy,
thereby preventing variations caused by different mosquito batches. After feeding, fully
engorged mosquitoes were frozen at -20˚ C (T0) or returned into the climate chamber for an
incubation period of 6, 12, 24, 36, 48, or 72 h post feeding (T6-72h). At each time point, 20 live
mosquitoes of each treatment condition were frozen at -20˚ C until sample analysis. Concen-
tration-time courses were plotted using GraphPad Prism 9.0.0. Mean values and standard
deviations (S2 Fig) or each single value (Fig 3) were illustrated.
Bioanalysis of the mosquito samples. Each mosquito was weighed on a precision balance
(Mettler Toledo, XP26 Excellence Plus, Ohio, USA) and placed into a 1.5 ml microtube that
contained 100 μl of the extraction solvent, a mixture of methanol:water (7,3 v/v) containing a
final concentration of 0.1% formic acid. The tissue was crushed with a cordless motor-driven
tissue grinder using disposable pellet pestles (DWK Life Sciences, Wertheim, Germany). The
grinding was performed until the mosquitoes were completely disintegrated. Afterwards, an
additional volume of 75 μl extraction solvent was added to the crushed mosquito samples. The
samples were mixed for 30 seconds in a multi tube vortex mixer (Marshall Scientific, Hamp-
ton, USA), sonicated for 10 min (Bandelin Sonorex ultrasonic bath, Faust, Schaffhausen, Swit-
zerland), and centrifuged for 10 min at 16.1 x g at room temperature (5415R micro-centrifuge,
Eppendorf, Hamburg, Germany). In a next step, 135 μl of the supernatant was transferred into
autosampler tubes and mixed with 15 μl internal standard solution (IS). The IS contained 125
ng/ml ivermectin-d2 and was prepared in a 1:1 (v/v) methanol:water mixture supplemented
with formic acid to a final concentration of 0.1%. Finally, the autosampler tubes were centri-
fuged (5810R centrifuge, Eppendorf) for 30 min at 15˚C and 3220 x g and placed into the auto-
sampler (10˚C) for subsequent liquid chromatography tandem mass spectrometry (LC-MS/
MS) analysis.
Mosquito extracts were analysed using a modular ultra-high-pressure liquid chromatogra-
phy (UPLC) system from Shimadzu (Kyoto, Japan) connected to an API 5500 QTRAP tandem
mass spectrometer (AB Sciex, Massachusetts, USA). A previously developed and validated
LC-MS/MS method for the quantification of ivermectin in human plasma and blood was used
for the analyses [41]. The method was slightly adapted in order to analyse ritonavir,
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ketoconazole, rifampicin, and piperonyl butoxide next to ivermectin. The compound specific
settings for all analytes are listed in S1 Table.
Reference stock solutions for calibration and quality control (QC) samples were prepared
in DMSO at a concentration of 1 mg/ml for ivermectin and 10 mg/ml for ritonavir, ketocona-
zole, rifampicin, and piperonyl butoxide. The reference solutions were mixed with methanol:
water (1:1, v/v) in a 1:100 (v/v) ratio in order to obtain a calibration and a QC working solution
mixture. These mixtures were then further diluted with blank mosquito matrix to a final con-
centration of 0.1 μg/ml ivermectin and 1 μg/ml for the other four analytes. A blank mosquito
matrix was produced by feeding mosquitoes drug-free human blood while following the same
extraction protocol as described above. Calibration and QC samples were prepared afterwards
by serial dilution in pooled blank mosquito extracts. The calibration ranges were 0.025–50 ng/
ml for ivermectin, 0.25–100 ng/ml for ketoconazole, 0.25–500 ng/ml for rifampicin, 0.25–1000
ng/ml for ritonavir, and 2.5–500 ng/ml for piperonyl butoxide. Each calibration set consisted
of one double blank (only matrix), a blank (matrix and IS) as well as up to 11 calibrators. QC
samples were prepared at low, mid, and high concentration so as to cover the entire calibration
range. For ivermectin QC samples with 0.1, 1, and 10 ng/ml were prepared, while the concen-
trations were ten times higher (1, 10, and 100 ng/ml) for ketoconazole, rifampicin, ritonavir,
and piperonyl butoxide.
Aliquots of 135 μl were transferred into autosampler tubes and stored at -20˚C. For each
PK analysis a set of calibration and QC samples were thawed, processed as for the PK samples,
and analysed at the beginning, middle, and end of the analytical run. The PK samples were
quantified with the Multi Quant software 3.0.3 (AB Sciex). The calibration points were fitted
by a linear regression model (weighted 1/x2) of the analyte concentration (x) against the peak
area ratio of the analyte and the IS (y). No IS was used for ketoconazole, rifampicin, ritonavir,
and piperonyl butoxide.
The correlation coefficient R of the calibration lines was in each analytical run larger than
0.997. The intra-run precision of ivermectin QC samples was�8% (n = 3), while the inter-run
precision was�6% (n = 12). The intra- and inter-run accuracy of ivermectin was between
99.8% to 107.2%, and 103.6% to 104.6%, respectively. The accuracy of the CYP modulator QC
samples was between 93.6% to 109.4% and the precision was�15%. These data indicate that
the bioanalytical method was reliable for the quantification of ivermectin as well as for the
CYP modulators in single mosquitoes.
Pharmacometric analysis. All analyses were performed on whole-body amounts of drug
in individual mosquitoes, i.e. the amount of drug detected in each mosquito specimen. As the
dose administered can vary depending on the feeding behaviour of individual mosquitoes, the
amount of drug taken up during the blood meal was estimated as an additional model parame-
ter (bioavailability of a standard dose, F1).
Data examination, analysis, and visualization were performed in GNU R (Version 3.5.3; R
Foundation for Statistical Computing, http://www.R-project.org, Vienna, Austria). Population
pharmacokinetic analysis was done using NONMEM (Version 7.4.3; Icon Development Solu-
tions, http://www.iconplc.com, Ellicott City, MD, USA) with the help of the Xpose and PsN
software packages for model diagnostics and testing of covariate relationships [42,43]. The
first order conditional estimation with eta-epsilon interaction (FOCE-I) was used throughout
the entire process.
For covariate model building, first a visual examination was done and covariates were
selected by clinical plausibility, after which the effect of weight (the only covariate available) on
structural model parameters was tested. Models were selected based on goodness-of-fit statis-
tics (objective function value (minus twice the log-likelihood)), graphical analysis using visual
predictive checks (VPCs, n = 1,000 simulations), and biological plausibility. Non-parametric
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bootstrap analysis (n = 1,000) was used to assess the precision of the estimates in the final
model.
Drug effect of the treatments
The drug effect on mosquito survival, fecundity and fertility was assessed over an incubation
period of four days in three replicates of 50 blood-fed mosquitoes for each condition; blank
human blood (negative control), blood with ivermectin (0.1 μg/mL), ritonavir (10 μg/mL),
ketoconazole (5 μg/mL), rifampicin (10 μg/mL), or PBO (10 μg/mL). In addition, drug combi-
nations of ivermectin (0.1 μg/ml) with either ritonavir (10 μg/ml), ketoconazole (5 μg/ml),
rifampicin (10 μg/ml), or piperonyl butoxide (10 μg/ml) were tested. Blood feeding was done
as described above. After the feeding, fully engorged mosquitoes were divided into groups of
25 per paper cup and placed in the climate chamber for 96 h. In contrast to the PK experi-
ments, the mosquitoes had unlimited access to water because a moistened oviposition sub-
strate was inserted into the paper cup.
The drug effect on mosquito survival was assessed by counting the living mosquitoes at 24,
48, 72 and 96 h post-treatment. Mosquitoes still moving upon physical contact were consid-
ered being alive.
Fecundity was defined as the total number of eggs laid after 96 h. The eggs were collected
inside the paper cups with a small petri dish (35 mm x 10 mm) that was padded with water-
soaked cotton wool and covered with filter paper (⌀: 42.5 mm, Whatman, Maidstone, United
Kingdom). The filter paper served as the oviposition substrate. The cotton wool was soaked
with fresh water and covered by a new filter paper after 48, 72, and 96 h post-treatment. After
the assay, the eggs were left to mature for 24 h in the insectary. The eggs were brushed carefully
from the filter paper into a new petri dish (35 mm x 10 mm) and weighed on a precision bal-
ance (Mettler Toledo, XP26 Excellence Plus, Ohio, USA) to estimate the amount of eggs laid
per treatment.
In order to evaluate the fertility of the mosquitoes, 100 eggs that were laid between 48 h and
72 h (n = 50) and between 72 h and 96 h (n = 50) post-treatment were immersed in 40 ml tap
water supplemented with 0.012% AquaSafe for 48 h. Any hatched larva was counted and trans-
ferred to a rearing tray with a plastic pipette. The fertility was calculated as the percentage of
eggs hatched.
Drug effects on mortality, fecundity, and fertility were performed in GNU R (Version 3.5.3;
R Foundation for Statistical Computing, http://www.R-project.org, Vienna, Austria). Normal-
ity was assessed using the Shapiro-Wilk test. For normally distributed data (mortality, fecun-
dity), group differences were assessed with one-way ANOVA testing, and, where applicable,
followed up with Tukey’s test. Group differences in fertility (not normally distributed) were
evaluated with Kruskal-Wallis one-way analysis of variance, and Wilcoxon rank sum testing as
post-hoc. P-values are reported with adjustment for multiple comparison and were considered
significant if p-value< 0.05.
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